Altimmune (ALT) Stock
Clinical stage biotech developing vaccines and treatments. Here's the price, business snapshot, and what's worth knowing about Altimmune in August 2026.
Altimmune Inc (ALT) is a clinical-stage biotechnology company focused on developing immunotherapies and vaccine candidates. As a small-cap business (market cap ~ $356.6M), it primarily derives value from its pipeline and clinical progress rather than steady revenue. Investors should know the stock is catalyst-driven: trial readouts, regulatory decisions and partner deals can produce significant share-price moves. That creates opportunity but also considerable risk — early-stage programmes are binary and timelines can be lengthy. Financial resources, partnerships and trial outcomes will shape valuation and dilution risk. This summary is general information for educational purposes and not personalised investment advice; suitability depends on your goals, risk tolerance and time horizon. Past performance is not indicative of future results and returns are not guaranteed.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Altimmune's stock with a target price of $20.15, indicating significant potential growth.
Financial Health
Altimmune is struggling with low revenue, but has some cash flow and book value support.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Catalyst-driven upside
Trial readouts and regulatory milestones can create sharp share-price moves; however, outcomes are binary and performance can vary.
Early-stage pipeline
An early-stage programme offers potential if trials succeed, but carries higher scientific and regulatory risk and possible dilution.
Partnerships matter
Collaborations or licensing deals can de-risk programmes and provide funding, yet they are not guaranteed and may take time to materialise.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
